FNCH Finch Therapeutics Group Inc.

Biotech Analyst Ratings

Latest News

1. 17 May 2022 Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference

   SOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery^® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. The presentation will be available on-demand beginning on Tuesday, May 24, 2022 at 7:00 am ET.
   

   A webcast of the presentation will be available under the ‘Investors & News' section of the Finch website and will be archived for approximately 30 days.

   About Finch Therapeutics

   Finch…

   View Full Article
2. 16 May 2022 Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

   • FDA lifted clinical hold on IND for CP101
     
   • Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022
   • $15 million drawn from new $55 million term debt facility
   • Anticipated cash runway into Q2 2024
   • Corporate update call today at 8am ET

   SOMERVILLE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

   "Finch made several important strides this quarter, including the resolution of…

   View Full Article
3. 09 May 2022 Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

   SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery^® platform to develop a novel class of orally administered biological drugs, today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights.
   

   The conference call can be accessed by dialing (833) 649-1186 (domestic) or (270) 823-1080 (international) and entering conference ID 8451806. The live webcast can be accessed by visiting the ‘Investors & News' section of the Finch Therapeutics website and selecting ‘Events …

   View Full Article
4. 28 April 2022 Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND

   SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery^® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Finch's investigational new drug (IND) application for CP101. CP101 is the Company's investigational orally administered microbiome therapeutic which is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI). The FDA lifted the clinical hold following a review of information Finch provided related to its SARS-CoV-2…

   View Full Article
5. 19 April 2022 Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

   SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery^® platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 20%. This workforce reduction will allow the company to focus its financial resources on its recurrent C. difficile infection (CDI) and autism spectrum disorder (ASD) development programs, two wholly-owned programs that Finch is prioritizing, along with its Takeda-partnered work in inflammatory bowel disease (IBD). Finch plans to provide guidance on the expected extension of the Company's…

   View Full Article